In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography
Figure 2
Tumor assessments of Xenografts U87MG and RAJI at 2 and 3 weeks after enzastaurin treatment. Standard caliper measurements show a tumor growth delay for U87MG ( at week 3), but not for RAJI (Panels (a) and (b). [F]FDG-PET imaging was performed at the same time as standard caliper measurements (Panels (c)-(d). Tumor glucose metabolism changes were measured by SUV (Panels (c), (d) and tumor/muscle ratio (Panels (e), (f) in U87MG and RAJI xenografts. Only in RAJI xenografts enzastaurin treatment showed a trend in increased SUV (Panel (d); at weeks 2 and 3). Using tumor/muscle ratio indicated a trend for FDG uptake in U87MG ( at week 3) (Panel (e), but not in RAJI xenografts (Panel (f). The tumor size assessment based on CT scan (Panels (g) and (h) indicated a trend for detecting reduced tumor size only in RAJI xenografts after enzastaurin treatment at week 2 (). Mice treated with vehicle alone are shown in green; mice treated with enzastaurin are shown in red, representation of 2 independent experiments.
